BeiGene (HKSE:06160) Total Assets : HK$46,026 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BeiGene Total Assets?

BeiGene's Total Assets for the quarter that ended in Dec. 2024 was HK$46,026 Mil.

During the past 12 months, BeiGene's average Total Assets Growth Rate was 25.10% per year. During the past 3 years, the average Total Assets Growth Rate was 19.80% per year. During the past 5 years, the average Total Assets Growth Rate was 38.10% per year. During the past 10 years, the average Total Assets Growth Rate was 83.10% per year.

During the past 12 years, BeiGene's highest 3-Year average Total Assets Growth Rate was 206.40%. The lowest was 19.80%. And the median was 65.70%.

Total Assets is connected with ROA %. BeiGene's annualized ROA % for the quarter that ended in Dec. 2024 was -10.33%. Total Assets is also linked to Revenue through Asset Turnover. BeiGene's Asset Turnover for the quarter that ended in Dec. 2024 was 0.19.

BeiGene Total Assets Historical Data

The historical data trend for BeiGene's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Total Assets Chart

BeiGene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

43,416.51

66,568.56

49,665.32

45,338.04

46,025.60

BeiGene Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial															45,338.04	44,338.27	44,612.12	45,428.23	46,025.60

BeiGene Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

BeiGene's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	25902.694	+	20122.907
	=	46,026

BeiGene's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	25902.694	+	20122.907
	=	46,026

BeiGene (HKSE:06160) Total Assets Explanation

Total Assets is connected with ROA %.

BeiGene's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-4722.528	/	( (45428.23	+	46025.602)	/ 2 )
	=	-4722.528	/	45726.916
	=	-10.33 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

BeiGene's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	8767.027	/	( (45428.23	+	46025.602)	/ 2 )
=	8767.027	/	45726.916
=	0.19

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

BeiGene Total Assets Related Terms

Thank you for viewing the detailed overview of BeiGene's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

BEIGF:USA ONC:USA 49B:Germany 688235:China B1ME34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

Executives

Jpmorgan Chase & Co.	2502 Approved lending agent
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Oyler John Victor	2101 Beneficial owner
Hhlr Advisors, Ltd.	2102 Investment manager
Hhlr Fund, L.p.	2101 Beneficial owner
Baker Brothers Life Sciences Capital, L.p.	2201 Interest of corporation controlled by you
Baker Felix James	2201 Interest of corporation controlled by you
Baker Julian Charles	2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc	2201 Interest of corporation controlled by you
Amgen Inc.	2101 Beneficial owner
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene Headlines

No Headlines